Abbott Can Sell St. Jude’s Intravascular Assessment Tools Under Expanded Alliance
This article was originally published in The Gray Sheet
Executive Summary
Rights for Abbott to promote and distribute intravascular optical coherence tomography imaging and fractional flow reserve products from St. Jude Medical are added to an existing co-promotion pact between the firms.
You may also be interested in...
Third Cardiovascular Giant Coming With $25 Bil. Abbott-St. Jude Deal
The previously rumored acquisition was announced on April 28, with the firms touting their extensive synergies in the cardiovascular space.
Abbott Denies St. Jude Acquisition Report, But Here's How The Firms Line Up
A media report stating Abbott was readying to buy St. Jude Medical was quickly shot down by the company. The firms do, though, have relatively complementary product portfolios
Fractional Flow Reserve Proves Itself Early In St. Jude’s FAME II Study
St. Jude Medical’s fractional flow reserve technology gave stenting a significant enough edge in stable coronary disease patients that a monitoring board recommended stopping the study early because it would be unethical to continue to randomize patients to the optimal medical therapy control group.